Goodwin Procter has published a legal guide to biosimilar drugs, a timely move, coming a week after the U.S. Food and Drug Administration indicated it is close to approving a biosimilar drug for the U.S. market for the first time.
When the news broke, the law firm was putting the finishing touches on its publication, “Biosimilars: A Guide to Regulatory and Intellectual Property Issues,” which is available through its website.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
